Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience

dc.contributor.authorErdogan, EGen_US
dc.contributor.authorYalta, TDen_US
dc.contributor.authorCan, Nen_US
dc.contributor.authorSüt, Nen_US
dc.contributor.authorTa?tekin, Een_US
dc.contributor.authorUsta, Uen_US
dc.contributor.authorPuyan, FOen_US
dc.contributor.authorUstural?, Keskin FEen_US
dc.contributor.authorKurt, BB.en_US
dc.date.accessioned2023-08-10T07:33:55Z
dc.date.available2023-08-10T07:33:55Z
dc.date.issued2023-09
dc.description.abstractBackground: Uterine carcinosarcomas (UCS) constitute 3–4% of all uterine malignancies and 16% of deaths caused due to uterine neoplasms. Aim: In this study, we aimed to perform DNA-based mutation analysis in 12 genes (KRAS, NRAS, EGFR, C-KIT, BRAF, PDGFRA, ALK, ERBB2, ERBB3, ESR1, RAF1, PIK3CA) to determine the molecular subtypes of UCS using next-generation sequencing (NGS) in patients with aggressive UCS and poor prognosis. We aimed to compare the results of our analysis with clinicopathological data to contribute to the development of targeted therapy approaches related to the molecular changes of UCS. Materials and Methods: In this study, we included 12 cases diagnosed with uterine carcinosarcomas and examined the changes in oncogenes that play a role in UCS pathogenesis. For the analysis of mutation, the clinicopathological data were compared with the variations in the DNA-based gene panel consisting of 12 genes and 1237 variants in the UCS using the NGS method. Results: EGFR mutation was found in 91.7% of the cases, mutation in 41.7%, PDGFRA mutation in 25%, KRAS and PIK3CA mutation in 16.7%, and C-KIT mutation in 8.3% of the cases. Although no statistical significance was found between the detected mutation and clinicopathological data, it was concluded that PDGFRA mutation might be associated with advanced-stage disease development. Conclusion: This study's findings regarding different molecular types of UCS and information on oncogenesis of UCS can provide inferences for targeted therapies in the future by identifying targetable mutations representing early oncogenic events and thereby contribute toward further studies on this subject.en_US
dc.identifier.affiliationsDepartment of Pathology, Faculty of Medicine, Trakya University, Edirne; Department of Pathology, Lüleburgaz State Hospital, K?rklareli, Turkeyen_US
dc.identifier.affiliationsDepartment of Pathology, Faculty of Medicine, Trakya University, Edirne, Turkeyen_US
dc.identifier.affiliationsDepartment of Biostatistics, Faculty of Medicine, Trakya University, Edirne, Turkeyen_US
dc.identifier.affiliationsDepartment of Pathology, Tekirda? State Hospital, Tekirda?, Turkeyen_US
dc.identifier.citationErdogan EG, Yalta TD, Can N, Süt N, Ta?tekin E, Usta U, Puyan FO, Ustural? Keskin FE, Kurt BB.. Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience. Indian Journal of Pathology & Microbiology. 2023 Sept; 66(3): 449-455en_US
dc.identifier.issn0377-4929
dc.identifier.issn0974-5130
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/223479
dc.languageenen_US
dc.publisherWolters Kluwer - Medknowen_US
dc.relation.issuenumber3en_US
dc.relation.volume66en_US
dc.source.urihttps://doi.org/10.4103/ijpm.ijpm_777_21en_US
dc.subjectMolecular analysisen_US
dc.subjectmolecular variationsen_US
dc.subjectmutationsen_US
dc.subjectnext-generation sequencingen_US
dc.subjectuterine carcinosarcomaen_US
dc.titleClinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experienceen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
IJPM2023v66n3p449.pdf
Size:
1.54 MB
Format:
Adobe Portable Document Format